GRAIL, Inc.

GRAIL, Inc.

GRAL·NASDAQ

$61.13

-5.1%
HealthcareMedical - Diagnostics & Research

GRAIL, Inc., a biotechnology company, focuses on developing technologies for early cancer detection. The company develops Galleri, a screening test for asymptomatic individuals over 50 years of age; and DAC, a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients for whom there is a clinical suspicion of cancer. It is also developing minimal residual disease and other post-diagnostic tests. The company was incorporated in 2015 and is based in Menlo Park, California. GRAIL, Inc. operates as a former subsidiary of Illumina, Inc.

At a Glance

Live Snapshot
Market Cap$2.62B
EPS-11.1100
P/E Ratio-5.50
Earnings Date08/11/2026

No Dividend Yield Data

GRAL has not reported any dividend yield values in the available annual periods.

No Dividend Payout Ratio Data

GRAL has not reported any dividend payout ratio values in the available annual periods.

No Net Dividends Paid Data

GRAL has not reported any net dividends paid values in the available annual periods.

GRAIL, Inc.

GRAIL, Inc. Dividend History

GRAL · NASDAQ
10Y CAGR +0%
Latest $0
Annual $0
Stable dividend payments
Last Period: +0%

GRAL Dividend Payment History

GRAL · NASDAQ
DeclarationEx-DatePayment DateDividendAdjustedFrequencyGrowth
No dividend payment history available
gral

GRAIL, Inc. Payout Ratio Analysis

GRAL · NASDAQ
Dividends Paid
0.00
2025
Net Income
-408.35M
2025
Payout Ratio
0.00%
2025

Dividend Sustainability Analysis

Payout Ratio
0.00%

Conservative payout with excellent safety margin. Company retains significant earnings for growth, acquisitions, or building cash reserves. Dividend is highly sustainable.

FCF Payout Ratio
0.0%

Negative free cash flow while paying dividends is a major red flag. Company burning cash and cannot sustain dividend without external financing.

Sustainability
At Risk

Dividend appears unsustainable based on current metrics. High probability of reduction or elimination. Proceed with caution.